4 stories this morning, for surgeons and the people who support them.
- FDA approves two-level use of Centinel Spine's prodisc C Nova, making three of Centinel's four cervical discs labeled for one or two contiguous levels — Centinel Spine release (PR Newswire, West Chester, Pa., October 14, 2026): FDA approved prodisc C Nova for two-level use; previously one-level only. Flat endplates and low-profile keels, prodisc CORE technology, in clinical use outside the U.S. since 2009, currently limited release in the U.S. Joins prodisc C Vivo and prodisc C SK (two-level approval October 2025), so three cervical TDR devices now carry one- and two-level labeling. Company claims prodisc is the only U.S. TDR platform approved for one- and two-level use in both cervical and lumbar spine (attributed in the script as the company's claim). No clinical data stated in the release. Independent verification: FDA PMA database (openFDA) lists P070001/S031, prodisc C Nova, Normal 180 Day Track supplement 'requesting expansion of the indications from one-level use to two', decision date 2026-09-09. Second outlet: ORTHOWORLD, October 14, 2026 (https://www.orthoworld.com/centinel-spine-gains-fda-approval-for-2-level-prodisc-c-nova/); also Orthopedics This Week reprint. Centinel's public S-1 (covered 2026-10-08) is the IPO context. Source
- Zimmer Biomet and THINK Surgical sign a multi-year extension of their exclusive distribution deal for a Persona-compatible version of the TMINI handheld knee robot — PR Newswire release, Fremont, Calif. and Warsaw, Ind., October 13, 2026 (Ortho Spine News; second source ORTHOWORLD, https://www.orthoworld.com/zimmer-biomet-and-think-surgical-extend-agreement/): multi-year extension of the Limited Exclusive Distribution and Supply Agreement after the initial term; Zimmer Biomet keeps distributing an exclusive version of the wireless, handheld TMINI Miniature Robotic System compatible with the Persona Knee. No length, financial terms or volumes disclosed. Quotes from Stuart Simpson (THINK CEO) and Brad Kessler (Zimmer Biomet President, Americas - Robotics, Technology and Data), who cites customers wanting a wireless handheld robot for Persona. Background: original agreement announced June 11, 2024 (Zimmer Biomet investor release; BioSpace), positioning TMINI alongside the ROSA portfolio as a handheld option working to a CT-based 3D plan; THINK then said it had partnerships with about 10 implant companies for an open platform. Source
- Patient-specific spine at NASS: Carlsmed starts the full U.S. launch of its aprevo lumbar bi-lateral posterior system as Globus previews its FDA-cleared SCRIPT patient-specific platform — Carlsmed (Nasdaq: CARL), GlobeNewswire October 14, 2026 (via ORTHOWORLD and GuruFocus, https://www.gurufocus.com/news/9123254/carlsmed-carl-launches-aprevo-lumbar-bilateral-posterior-system-at-nass-2026): U.S. commercial launch of the aprevo Lumbar Bi-lateral Posterior System, after a limited market evaluation that began in February 2026 with a first in-human case on February 10, 2026; direct posterior approach; CEO Mike Cordonnier says it is 'optimized to support planned three-dimensional correction of the spine.' Globus Medical (NYSE: GMED) release October 14, 2026 (Ortho Spine News, https://orthospinenews.com/2026/10/14/globus-medical-to-showcase-script-patient-specific-implants-and-new-xlif-prone-procedural-solution-at-nass-2026/; also MarketScreener): exclusive preview at NASS of SCRIPT, its first patient-specific spinal implant platform, 'moving toward commercialization' with no launch date; SCRIPT Studio lets surgeons plan alignment, implant position and geometry and fixation, with plans importable into ExcelsiusGPS or ExcelsiusHub; also a new XLIF Prone Procedural Solution (prone positioner plus MaXcess Air two-blade retractor). FDA 510(k) database (openFDA): K253401 SCRIPT Implant System, lumbar interbody with integrated fixation, decided 2026-04-29; K253739 SCRIPT Rods, decided 2026-05-07. Context from prior episodes: new FY2027 fusion MS-DRGs effective October 1 are device-class, not Carlsmed-exclusive (2026-08-31); ORTHOWORLD puts Medtronic and Globus at a combined 43% of the spine market (2026-09-22). Source
- JBJS: 791 anatomic total shoulders from Florida Orthopaedic Institute show 96% implant survival at 10 years, but 69.5% of shoulders at the patient-acceptable threshold — Kucharik MP, ... Frankle MA. 'Defining Long-Term Success After Anatomic Total Shoulder Arthroplasty: Survivorship and Clinically Important Outcomes.' J Bone Joint Surg Am. 2026 Oct 9, online ahead of print; doi 10.2106/JBJS.26.00452; PMID 42853908. University of South Florida / Florida Orthopaedic Institute / Foundation for Orthopaedic Research and Education, Tampa. Retrospective cohort, 791 consecutive aTSAs, 2003 to 2015. Kaplan-Meier survivorship 96.1% at 10 years, 93.7% at 15. Walch B glenoid and younger age independently associated with revision. At the 10-year landmark the anchor-based ASES PASS threshold was 68.1 (achieved by 69.5%); MCID 14.0 and SCB 39.2 (achieved by 79.9% and 55.8%). Function attenuated gradually. Younger age, primary glenohumeral OA and lower preoperative ASES predicted SCB. Prognostic Level III; no external funding. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.